Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

59.17 -1.40 (-2.31%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
What 5 Analyst Ratings Have To Say About Globus Medical
Globus Medical (NYSE:GMED) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Globus Medical's Return On Invested Capital Insights
Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) posted Q1 earnings of $38.08 million, an increase from Q4 of 152.11%. Sales dropped to $230.55 million, a 7.79% decrease between quarters. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Globus Medical
Analysts have provided the following ratings for Globus Medical (NYSE:GMED) within the last quarter: 
Via Benzinga
Globus Medical: Q1 Earnings Insights
Globus Medical (NYSE:GMED) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings Globus Medical missed estimated... 
Via Benzinga
Globus Medical Issues Softer Outlook For Q1, CEO Resigns
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Where Globus Medical Stands With Analysts
Analysts have provided the following ratings for Globus Medical (NYSE:GMED) within the last quarter: 
Via Benzinga
Globus Medical's Q4 Earnings Beat Estimates, But FY22 Outlook Lags
Globus Medical Inc's (NYSE: GMED) Q4 sales rea 
Via Benzinga
Globus Medical: Q4 Earnings Insights
Globus Medical (NYSE:GMED) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:15 PM. Here's what investors need to know about the announcement. 
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Health Care Stocks Could Use A Surgical Boom — Will It Happen For Stryker, Boston Scientific, Others?
Elective procedures are recovering slowly as Covid cases decline. Will they ever boom? 
Via Investor's Business Daily
Globus Medical's Return on Invested Capital Insights
Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) showed a loss in earnings since Q3, totaling $15.11 million. Sales, on the other hand, increased by 8.84% to $250.02... 
Via Benzinga
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022
Upgrades 
Via Benzinga
Expert Ratings For Globus Medical
Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
Earnings Preview: Globus Medical
Globus Medical (NYSE:GMED) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Globus Medical... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022
Upgrades According to Vertical Research, the prior rating for Livent Corp (NYSE: 
Via Benzinga
Why Did BofA Securities Give Globus Medical A Double Upgrade?
Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021
Upgrades According to B of A Securities, the prior rating for Globus Medical Inc (NYSE: 
Via Benzinga
Data Rules All in RYAH Group's IoT Solution for Plant-Based Medicine
Photo by Franki Chamaki on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Were Hedge Funds Right About Hyatt Hotels Corporation?
The largest stake in Hyatt Hotels Corporation was held by Melvin Capital Management, which reported holding $283.4 million worth of stock at the end of June. 
Via Talk Markets
Globus Medical (GMED) Q3 2021 Earnings Call Transcript
GMED earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Recap: Globus Medical Q3 Earnings
Globus Medical (NYSE:GMED) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Return on Capital Employed Insights for Globus Medical
After pulling data from Benzinga Pro it seems like during Q2, Globus Medical (NYSE:GMED) earned $59.75 million, a 8.98% increase from the preceding quarter. Globus Medical also... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS